Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958954 · ClinicalTrials.gov registry record
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
A clinical trial, sponsored by ModernaTX.
- Completed
- Registry status
- 50,000,000
- Enrollment target
NCT04958954 is a clinical trial that has completed, run by ModernaTX. The registered enrollment target is 50,000,000 participants.
The verdict
NCT04958954 has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- 50,000,000 participants
- Enrollment target
Study Summary
The goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the SARS-CoV-2 mRNA-1273 vaccine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50,000,000 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2023-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04958954
The ClinicalTrials.gov registry entry for NCT04958954 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50,000,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04958954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04958954 about?
NCT04958954 is a clinical study titled "Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States". The goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the SARS-CoV-2 mRNA-1273 vaccine.
What is the current status of trial NCT04958954?
This trial is currently completed. The enrollment target is 50,000,000 participants. The study started on 2021-07-07. Estimated completion is 2023-06-30.
Who is sponsoring clinical trial NCT04958954?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.